查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862930

靜脈注射免疫球蛋白市場依最終用戶、產品類型、患者類型、通路和適應症分類－2025-2032年全球預測

Intravenous Immunoglobulin Market by End User, Product Type, Patient Type, Distribution Channel, Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，靜脈注射免疫球蛋白市場規模將達到 23.1 億美元，複合年成長率為 7.12%。

主要市場統計數據
基準年 2024 13.3億美元
預計年份：2025年 14.3億美元
預測年份：2032年 23.1億美元
複合年成長率 (%) 7.12%

本書清晰權威地闡述了靜脈注射免疫球蛋白如何成為現代免疫療法在各種臨床環境和不斷變化的監管要求中的基礎。

靜脈注射免疫球蛋白在現代免疫療法中發揮核心作用，是多種臨床適應症的重要治療方法。臨床醫生依靠這些血漿衍生產品來調節自體免疫疾病、血液系統疾病、免疫力缺乏以及某些神經系統疾病的免疫反應。在現代醫學中，靜脈注射免疫球蛋白因其作用機制廣泛且適用於住院、門診病人和專科護理等多種醫療環境而備受青睞，其產品組合涵蓋了臨床急症和長期疾病管理。

生產製造創新、完善的臨床指南以及監管機構對可追溯性的重視，正在重塑靜脈注射免疫球蛋白的供應鏈和治療用途。

靜脈注射免疫球蛋白領域正經歷著變革性的轉變，這主要得益於生產技術的進步、臨床實踐的轉變以及監管機構對產品來源的日益重視。新的生產方法以及改進的純化和製劑技術降低了不利事件的發生率，延長了保存期限，並實現了液體劑型的穩定性，從而影響了醫院的用藥決策和門診給藥模式。同時，臨床醫生也在根據不斷累積的真實世界數據最佳化適應症和給藥策略，使臨床指南與實際應用更加契合。

關稅變化對全球血漿採購、生產經濟性和免疫球蛋白療法採購韌性的連鎖反應

關稅及相關貿易措施的實施可能會對嚴重依賴跨境血漿採購和國際生產網路的全球治療領域產生連鎖反應。影響原料、包裝材料或成品的關稅調整可能會對採購團隊和醫院藥房造成額外的成本壓力，迫使製造商重新評估其籌資策略以及與供應商和經銷商的合約結構。作為應對措施，企業可能會尋求促進本地生產或實現供應鏈多元化，以減少對單一貿易體系的依賴。

將市場進入趨勢與醫療環境、產品配方、患者人口統計特徵、分銷管道和臨床適應症聯繫起來的綜合細分分析

對細分市場的詳細分析揭示了臨床需求、製劑偏好和分銷管道趨勢相互交織，共同塑造使用模式的領域。最終使用者考慮涵蓋居家醫療、醫院和專科診所等場所，其中醫院進一步細分為私立和公立機構，專科診所則細分為血液科、免疫科和神經科。這些區分至關重要，因為管理環境會影響管理物流、監控要求和合約方式。私立醫院和專科診所通常與公立醫院協商不同的報銷和採購條款，而居家醫療需要與護理服務部門協調並進行低溫運輸配送。

影響美洲、歐洲、中東和非洲以及亞太地區供應鏈韌性、監管力度和臨床應用模式的區域趨勢

區域趨勢塑造了從捐贈血漿到患者的治療路徑，每個宏觀區域都有其獨特的監管、物流和需求側因素。在美洲，完善的血漿採集基礎設施、臨床醫生對靜脈注射免疫球蛋白適應症的深刻理解以及先進的醫院環境促進了其廣泛應用，而區域支付方的政策和採購框架則影響著產品的選擇和合約簽訂方式。公立和私立醫療保健系統之間的差異、專科診所的作用以及門診輸液服務的密度，都會影響全部區域的治療方法實施和報銷方式。

對血漿來源、生產規模和臨床證據的策略性投資如何使領先的生產商和分銷合作夥伴脫穎而出

產業主要參與者正努力應對複雜的市場環境，在這個環境中，規模、供應安全和合規性至關重要。主要企業正投資於上游血漿來源、擴大血漿分離生產能力，並加強病原體減少和分析檢測，以提高產品的安全性和一致性。血漿採集網路與生產者之間的策略聯盟日益普遍，旨在確保原料來源並降低供應中斷的風險。同時，各公司正透過改進製劑技術、拓展適應症產品系列以及附加價值服務（例如患者援助計劃和輸液中心合作）來實現差異化競爭。

為製造商和供應商提供切實可行的策略，以確保供應鏈安全、增強臨床應用機會並最佳化商業管道。

產業領導者應採取多維度策略，平衡供應韌性、臨床參與和商業性靈活性。加強與血漿採集網路的上游夥伴關係，並投資區域血漿分離能力，將有助於縮短前置作業時間，同時降低貿易中斷和關稅風險。同時，透過投資改進配方和分析方法來增強產品差異化，將有助於提升產品在醫保目錄的排名，並推動其在住院和門診環境中的應用。

為了檢驗關鍵發現，我們採用了嚴格的混合方法研究框架，結合了專家訪談、監管分析和供應鏈情境分析方法。

我們的研究途徑結合了多方面的證據基礎和系統性檢驗，以確保研究結果的可靠性和可操作性。主要研究包括對血液科、免疫科和神經科的專科臨床醫生、公立和私立醫院的採購人員、藥屋主任以及血漿採集和分離機構的高級管理人員進行深度訪談。這些訪談提供了關於臨床實踐、合約動態和營運限制的詳細觀點，並用於檢驗從二手資訊中觀察到的趨勢。

整合不斷變化的臨床、運作和政策因素，這些因素決定了免疫球蛋白療法的可及性、安全性和治療價值。

儘管靜脈注射免疫球蛋白仍然是治療多種免疫學、血液學和神經病學疾病的關鍵治療方法，但其研發、採購和供應模式正在迅速變化。生產技術的進步和更嚴格的監管要求提高了產品品質和安全性，而供應鏈策略和區域供給能力的轉變正在重塑其獲取途徑。臨床醫生、支付者和醫療系統將越來越重視循證用藥、透明且穩健的採購管道，以確保治療的連續性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 生物類似免疫球蛋白上市對標準靜脈注射免疫球蛋白療法定價和應用的影響
  • 透過整合個體化給藥演算法最佳化靜脈注射免疫球蛋白療法的效率和療效
  • 擴大靜脈注射免疫球蛋白在自體免疫神經系統疾病和罕見疾病治療的應用
  • 供應鏈多元化策略旨在緩解血漿短缺並確保靜脈注射免疫球蛋白（IVIG）的穩定供應。
  • 監管協調工作旨在加速下一代靜脈注射免疫球蛋白產品的全球核准
  • 分餾過程的技術進步提高了靜脈注射免疫球蛋白產品的純度和安全性。
  • 靜脈注射免疫球蛋白（IVIG）在皮膚疾病中的仿單標示外使用日益增多，促使人們進行新的臨床安全性研究。
  • 過渡到居家靜脈注射免疫球蛋白（IVIG）模式可提高患者的便利性和醫療保健成本效益。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依最終使用者分類的靜脈注射免疫球蛋白市場

  • 居家醫療
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專科診所
    • 血液科診所
    • 免疫診所
    • 神經內科診所

9. 依產品類型分類的靜脈注射免疫球蛋白市場

  • 高純度免疫球蛋白
  • 通常是免疫球蛋白
    • 液體
    • 凍乾產品

10. 依患者類型分類的靜脈注射免疫球蛋白市場

  • 成人
  • 老年人
  • 兒童

11. 依分銷管道分類的靜脈注射免疫球蛋白市場

  • 直銷
  • 醫院藥房
  • 零售藥房
  • 批發商

12. 依適應症分類的靜脈注射免疫球蛋白市場

  • 自體免疫疾病
    • Guillain-Barré二氏症候群
    • 免疫性血小板缺乏紫斑症
    • 川崎病
  • 血液疾病
    • 新生兒溶血病
  • 免疫力缺乏
    • 原發性免疫力缺乏缺陷症
    • 次發性免疫力缺乏
  • 神經系統疾病
    • 慢性脫髓鞘多發性神經炎
    • 多灶性運動神經病變

13. 各地區靜脈注射免疫球蛋白市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 依組別分類的靜脈注射免疫球蛋白市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國靜脈注射免疫球蛋白市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • CSL Limited
    • Grifols, SA
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Baxter International Inc.
    • BIoTest AG
    • Bio Products Laboratory Limited
    • Kedrion SpA
    • LFB SA
    • Shanghai RAAS Blood Products Co., Ltd.
Product Code: MRR-FF012EDC38B0

The Intravenous Immunoglobulin Market is projected to grow by USD 2.31 billion at a CAGR of 7.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.33 billion
Estimated Year [2025] USD 1.43 billion
Forecast Year [2032] USD 2.31 billion
CAGR (%) 7.12%

A clear, authoritative framing of how intravenous immunoglobulin underpins modern immunotherapy across diverse clinical settings and evolving regulatory expectations

Intravenous immunoglobulin occupies a central role in modern immunotherapy, serving as a critical therapeutic modality across a diverse set of clinical indications. Clinicians rely on these plasma-derived preparations to modulate immune responses in autoimmune, hematological, immunodeficiency, and selected neurological disorders. In contemporary practice, intravenous immunoglobulin is valued both for its broad mechanism of action and for its adaptability across inpatient, outpatient, and specialty care settings, making it a product class that intersects clinical urgency and long-term disease management.

Recent advances in manufacturing and quality control have elevated product consistency and safety profiles, while regulatory scrutiny and supply chain dynamics continue to shape access and utilization. The therapeutic landscape is being influenced by evolving clinical guidelines, greater emphasis on evidence-based use, and the integration of novel indications supported by emerging clinical data. As a result, stakeholders from clinicians to procurement leaders need nuanced insights into how clinical practice, manufacturing scale, and distribution channels interact to determine availability, therapeutic sequencing, and patient outcomes.

How manufacturing innovation, clinical guideline refinement, and regulatory emphasis on traceability are reshaping supply chains and therapeutic use of intravenous immunoglobulin

The intravenous immunoglobulin landscape is undergoing transformative shifts driven by advances in manufacturing, changing clinical practice, and heightened regulatory emphasis on product provenance. New manufacturing approaches and improvements in purification and formulation have reduced adverse event profiles and enabled longer shelf life and more stable liquid presentations, which in turn influence hospital formulary decisions and outpatient administration models. Concurrently, clinicians are refining indications and dosing strategies based on accumulating real-world evidence, prompting tighter alignment between clinical guidelines and utilization.

Supply chain resilience has become a strategic priority as plasma sourcing, donor recruitment, and international logistics face increasing scrutiny. This has spurred vertical integration, strategic partnerships between plasma suppliers and manufacturers, and investment in regional processing capacity. Regulatory agencies are emphasizing traceability and pathogen safety, and health systems are responding with more rigorous procurement standards and contingency planning. Collectively, these shifts are altering where and how intravenous immunoglobulin is produced, distributed, and administered, pressing industry participants to innovate across clinical, operational, and commercial domains.

The cascading effects of tariff changes on global plasma sourcing, production economics, and procurement resilience for immunoglobulin therapies

The imposition of tariffs and related trade measures can have a cascading influence on a global therapeutic class that depends heavily on cross-border plasma procurement and international manufacturing networks. Tariff adjustments affecting inputs, packaging materials, or finished products introduce additional cost pressure that procurement teams and hospital pharmacies must manage, and they can prompt manufacturers to re-evaluate sourcing strategies and contractual structures with suppliers and distributors. In response, firms may pursue localized production or diversify supplier bases to reduce exposure to a single trade regime.

Beyond immediate cost implications, tariffs influence contract negotiations and long-term strategic choices. They may accelerate moves toward regionalization of supply chains, encourage investments in domestic plasma collection and fractionation, or alter the economics of exporting finished product. Payers and hospital systems may shift purchasing patterns to prioritize products with more predictable landed costs, and manufacturers might adapt pricing structures or absorb a portion of tariff-related expenses to maintain competitive positioning. Ultimately, tariffs reshape the calculus around procurement resilience, supplier relationships, and regional manufacturing footprints in ways that require proactive commercial and operational adjustments.

Comprehensive segmentation analysis linking care settings, product formulations, patient demographics, distribution channels, and clinical indications to access dynamics

A granular view of segmentation reveals where clinical demand, formulation preferences, and channel dynamics intersect to shape utilization patterns. End-user considerations span home care, hospital, and specialty clinic settings, with hospitals further differentiated into private and public institutions and specialty clinics segmenting into hematology, immunology, and neurology practices. These distinctions matter because administration setting influences dosing logistics, monitoring requirements, and contracting approaches; private hospitals and specialty clinics often negotiate different reimbursement and procurement terms than public hospitals, and home care requires coordination with nursing services and cold-chain delivery.

Product-type segmentation distinguishes high purity immunoglobulin from standard preparations, and among standard products the formulation choice between liquid and lyophilized options affects storage, reconstitution workflow, and suitability for different care settings. Patient type segmentation identifies adult, geriatric, and pediatric populations, each with unique dosing paradigms and safety considerations that influence clinical protocols and payer coverage decisions. Distribution channel segmentation captures direct sales, hospital pharmacy supply, retail pharmacy dispensing, and wholesale distribution pathways, reflecting how procurement, inventory management, and service-level agreements vary across stakeholders. Indication-based segmentation encompasses autoimmune diseases, hematological conditions, immunodeficiency disorders, and neurological disorders, with autoimmune subcategories such as Guillain-Barre syndrome, immune thrombocytopenic purpura, and Kawasaki disease; hematological focus on hemolytic disease of the newborn; immunodeficiency subtypes including primary and secondary forms; and neurological emphasis on chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Integrating these segmentation lenses clarifies where clinical demand concentrates, how supply models must adapt, and which channels are most critical for timely patient access.

Regional dynamics driving supply chain resilience, regulatory rigor, and clinical adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape how therapies move from donor plasma to patients, and each macro-region presents distinct regulatory, logistical, and demand-side factors. In the Americas, established plasma collection infrastructure, strong clinician familiarity with intravenous immunoglobulin indications, and advanced hospital settings support broad utilization, while regional payer policies and procurement frameworks influence product selection and contracting approaches. Differences between public and private systems, the role of specialized clinics, and the density of outpatient infusion services all affect how therapies are administered and reimbursed across the region.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with national pricing and reimbursement variability. Several countries in this region emphasize stringent traceability and pathogen safety requirements, and both public procurement mechanisms and private specialty networks play roles in access. Investment in regional fractionation capacity and growing attention to supply security are shaping strategic priorities. In Asia-Pacific, rapid healthcare infrastructure expansion, rising clinical adoption across tertiary centers, and increasing investment in plasma collection capacity are notable. However, challenges persist related to distribution logistics, cold-chain reliability, and alignment between clinical guideline adoption and payer coverage. Taken together, regional differences influence manufacturer strategy, clinical adoption timelines, and the design of distribution partnerships to ensure consistent patient access.

How strategic investments in plasma sourcing, manufacturing scale, and clinical evidence are differentiating leading producers and distribution partners

Key industry participants are navigating a complex environment that rewards scale, supply security, and regulatory compliance. Leading firms are investing in upstream plasma sourcing, expanding fractionation capacity, and enhancing pathogen reduction and analytical testing to strengthen product safety and consistency. Strategic alliances between plasma collection networks and manufacturers are increasingly common, aiming to secure raw material streams and reduce exposure to supply disruptions. At the same time, companies are differentiating through formulation advances, portfolio breadth across indications, and value-added services such as patient support programs and infusion center partnerships.

Competitive dynamics also reflect varied go-to-market models: some organizations emphasize direct sales to large hospital systems and integrated health networks, while others prioritize distribution via hospital pharmacies, retail channels, or wholesale partners to reach a broader clinical base. Mergers, targeted acquisitions, and technology partnerships that improve manufacturing yield or reduce cycle time are shaping the competitive map. Additionally, a focus on evidence generation, real-world outcomes studies, and targeted clinical programs is enhancing payer conversations and supporting label expansions or guideline inclusion for new and established indications.

Practical strategic moves for manufacturers and suppliers to secure supply chains, strengthen clinical access, and optimize commercial channel alignment

Industry leaders should adopt a multidimensional strategy that balances supply resilience, clinical engagement, and commercial agility. Strengthening upstream partnerships with plasma collection networks and investing in regional fractionation capabilities will reduce exposure to trade disruptions and tariffs while improving lead times. Simultaneously, enhancing product differentiation through formulation improvements and investment in analytical methods will support formulary positioning and facilitate adoption across inpatient and outpatient settings.

Commercially, organizations should tailor channel strategies to account for differences in direct hospital procurement, hospital pharmacy distribution, retail dispensing, and wholesale networks, and align contracting and value propositions with the specific needs of private versus public institutions and specialty clinics. Clinically, partnering with key opinion leaders across hematology, immunology, and neurology to build robust real-world evidence can accelerate guideline adoption and clarify appropriate utilization across adult, geriatric, and pediatric populations. Finally, firms should implement dynamic pricing and risk-sharing mechanisms that address payer concerns while preserving access, and maintain transparent communication with regulators and health systems to anticipate policy shifts and ensure uninterrupted patient care.

A rigorous mixed-methods research framework blending expert interviews, regulatory analysis, and supply-chain scenario techniques to validate key insights

The research approach combined a multi-source evidence base with structured validation to ensure robust findings and actionable insights. Primary research included in-depth interviews with clinicians across hematology, immunology, and neurology specialties, procurement leaders from private and public hospitals, pharmacy directors, and senior executives in plasma collection and fractionation organizations. These conversations provided granular perspectives on clinical practice, contracting dynamics, and operational constraints, and were used to validate trends observed in secondary sources.

Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, manufacturing quality standards, and publicly available filings and technical materials. Analytical methods integrated qualitative synthesis of stakeholder interviews with process mapping of supply chains, scenario analysis of trade and tariff impacts, and comparative review of formulation and distribution models. Quality assurance steps included cross-validation of interview findings against regulatory and clinical literature, internal expert review, and methodological transparency about data limitations and potential biases. This layered approach ensured the report's conclusions rested on convergent evidence and practitioner-informed interpretation.

Synthesis of the evolving clinical, operational, and policy drivers that will determine access, safety, and therapeutic value for immunoglobulin therapies

Intravenous immunoglobulin remains a cornerstone therapy across a range of immunologic, hematologic, and neurologic indications, but the environment in which it is developed, sourced, and delivered is evolving rapidly. Manufacturing advances and tighter regulatory expectations have improved product quality and safety, while shifts in supply chain strategy and regional capacity are reshaping access dynamics. Clinicians, payers, and health systems will increasingly demand evidence-aligned use, transparent provenance, and resilient procurement pathways to ensure continuity of care.

Looking ahead, stakeholders who proactively invest in secure plasma sourcing, flexible manufacturing footprints, and rigorous clinical evidence generation will be best positioned to navigate tariff pressures, distribution complexities, and shifting care models. Cross-sector collaboration among manufacturers, plasma collection networks, clinicians, and payers will be essential to sustain availability and to optimize therapeutic value for patients across diverse care settings and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of biosimilar immunoglobulin launches on pricing and adoption of standard IVIG therapies
  • 5.2. Integration of personalized dosing algorithms to optimize IVIG treatment efficiency and outcomes
  • 5.3. Growing use of intravenous immunoglobulin in autoimmune neurology and rare disease therapies landscape
  • 5.4. Supply chain diversification strategies to mitigate raw plasma shortages and ensure IVIG availability
  • 5.5. Regulatory harmonization initiatives accelerating approval of next generation IVIG formulations globally
  • 5.6. Technological advancements in fractionation processes driving higher purity and safety of IVIG products
  • 5.7. Increasing off-label use of IVIG in dermatological conditions driving new clinical safety studies
  • 5.8. Shifts towards home-based IVIG administration models enhancing patient convenience and healthcare cost efficiencies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intravenous Immunoglobulin Market, by End User

  • 8.1. Home Care
  • 8.2. Hospital
    • 8.2.1. Private Hospital
    • 8.2.2. Public Hospital
  • 8.3. Specialty Clinic
    • 8.3.1. Hematology Clinic
    • 8.3.2. Immunology Clinic
    • 8.3.3. Neurology Clinic

9. Intravenous Immunoglobulin Market, by Product Type

  • 9.1. High Purity Immunoglobulin
  • 9.2. Normal Immunoglobulin
    • 9.2.1. Liquid
    • 9.2.2. Lyophilized

10. Intravenous Immunoglobulin Market, by Patient Type

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Intravenous Immunoglobulin Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Hospital Pharmacy
  • 11.3. Retail Pharmacy
  • 11.4. Wholesale Distributor

12. Intravenous Immunoglobulin Market, by Indication

  • 12.1. Autoimmune Diseases
    • 12.1.1. Guillain-Barre Syndrome
    • 12.1.2. Immune Thrombocytopenic Purpura
    • 12.1.3. Kawasaki Disease
  • 12.2. Hematological Conditions
    • 12.2.1. Hemolytic Disease Of The Newborn
  • 12.3. Immunodeficiency Disorders
    • 12.3.1. Primary Immunodeficiency
    • 12.3.2. Secondary Immunodeficiency
  • 12.4. Neurological Disorders
    • 12.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 12.4.2. Multifocal Motor Neuropathy

13. Intravenous Immunoglobulin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Intravenous Immunoglobulin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Intravenous Immunoglobulin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. CSL Limited
    • 16.3.2. Grifols, S.A.
    • 16.3.3. Takeda Pharmaceutical Company Limited
    • 16.3.4. Octapharma AG
    • 16.3.5. Baxter International Inc.
    • 16.3.6. Biotest AG
    • 16.3.7. Bio Products Laboratory Limited
    • 16.3.8. Kedrion S.p.A.
    • 16.3.9. LFB S.A.
    • 16.3.10. Shanghai RAAS Blood Products Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORD